This is a prospective, single-arm, multicenter trial designed to further evaluate the performance of the MarrowStim™ PAD Kit to treat critical limb ischemia (CLI) in subjects deemed unsuitable for revascularization. If subjects become eligible for conventional revascularization (i.e. bypass, PTA, etc.) following enrollment (due to improvement of condition, change of circumstances, etc.), they will not be denied treatment.